Keywords: nippon, boeh, ing, again, records, fastest, growth
Nippon Boeh Ing again records fastest growth in Japan's ethical drug market
Article | 28 April 2008
The Japanese subsidiary of Boehringer Ingelheim, the privately-owned German pharmaceutical major, is aiming for sales of 200.0 billion yen ($1.98 billion) in 2010, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
